Search
Login

If you are a member of the general public and not a healthcare professional, NOVELTY study investigator or AstraZeneca Medical employee, please CLICK HERE to see information tailored to you.

Our Mission

The NOVEL observational longiTudinal studY (NOVELTY) is a global, prospective, 3-year observational study of patients with a diagnosis or suspected diagnosis of asthma and/or COPD, with an additional 2-year extension study at participating sites. NOVELTY aims to describe patient characteristics, treatment patterns and disease burden over time across the spectrum of obstructive lung disease, providing real-world evidence to advance the development of precision medicine to deliver the right treatment to the right patient at the right time. The NOVELTY study is sponsored by AstraZeneca.

Information for the general public

Deep learning approach for lung cavity estimation manuscript published

Now published in the Journal of Magnetic Resonance Imaging: A dual-channel deep learning approach for lung cavity estimation from hyperpolarized gas and proton MRI.

Read More

GOLD 2023 cites NOVELTY article on treatable traits

The newly published GOLD 2023 report cites the ‘Treatable traits in the NOVELTY study’ article.

Read More

NOVELTY frequent productive cough manuscript published

Now published in Respiratory Medicine: Frequent productive cough: Symptom burden and future exacerbation risk among patients with asthma and/or COPD in the NOVELTY study.

Read More

Publications & presentations

Read summaries of publications and presentations relating to the NOVELTY study and access useful NOVELTY resources.

Read More

For investigators

Access news updates, research requests, resources and frequently asked questions relating to the NOVELTY study.

Read More

For AstraZeneca Medical employees

Access news updates, research requests, resources and frequently asked questions relating to the NOVELTY study.

Read More
19 PARTICIPATING COUNTRIESa
~12,000 ENROLLED PATIENTSa
84% OF PATIENTS HAVE SPIROMETRY DATAb

You are now leaving: http://aznoveltyproject.com/

By following this link you will be leaving the NOVELTY study website.

Please note that AstraZeneca does not take responsibility for the content displayed on other websites.

Continue Return to NOVELTY study